相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sex difference in patients with controlled acromegaly-A multicentre survey
Jakob Dal et al.
CLINICAL ENDOCRINOLOGY (2023)
Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
Monica Gadelha et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
The Future of Somatostatin Receptor Ligands in Acromegaly
Monica R. Gadelha et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length
Francesco Cocchiara et al.
PITUITARY (2022)
Pasireotide-a novel somatostatin receptor ligand after 20 years of use
Marek Bolanowski et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2022)
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial
Maria Fleseriu et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
Maria Stelmachowska-Banas et al.
PITUITARY (2022)
Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
Alessandro Mondin et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
A Pituitary Society update to acromegaly management guidelines
Maria Fleseriu et al.
PITUITARY (2021)
More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
Maria Fleseriu et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
Przemyslaw Witek et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
Maria Fleseriu et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Global epidemiology of acromegaly : a systematic review and meta-analysis
Salvatore Crisafulli et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
Susan L. Samson et al.
PITUITARY (2021)
The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
C. Simeoli et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
Monica Gadelha et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Octreotide-Resistant Acromegaly: Challenges and Solutions
Giuliana Corica et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Pasireotide for acromegaly: long- term outcomes from an extension to the Phase III PAOLA study
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Multidisciplinary management of acromegaly: A consensus
Andrea Giustina et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
Monica R. Gadelha et al.
ENDOCRINE CONNECTIONS (2020)
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly
Federico Gatto et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2019)
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
Federico Gatto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
How to Position Pasireotide LAR Treatment in Acromegaly
Eva C. Coopmans et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells
Federico Gatto et al.
PITUITARY (2019)
Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
Helene Lasolle et al.
ENDOCRINE CONNECTIONS (2019)
The position of combined medical treatment in acromegaly
Eva C. Coopmans et al.
ARCHIVES OF ENDOCRINOLOGY METABOLISM (2019)
Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)
Ammar Muhammad et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Personalized medicine in the treatment of acromegaly
Leandro Kasuki et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review
Michiel J. van Esdonk et al.
PITUITARY (2018)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study
A. Albani et al.
ENDOCRINE (2018)
Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study
Ilan Shimon et al.
ENDOCRINE (2018)
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database
Federico Gatto et al.
ENDOCRINE (2018)
Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naive patients with acromegaly: data from the PRIMARYS study
Philippe J. Caron et al.
CLINICAL ENDOCRINOLOGY (2017)
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas
Federico Gatto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors
Harish Babu et al.
NEUROSURGERY (2017)
Somatostatin receptor ligands in the treatment of acromegaly
Monica R. Gadelha et al.
PITUITARY (2017)
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities
Rosario Pivonello et al.
PITUITARY (2017)
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Annamaria Colao et al.
PITUITARY (2016)
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly
Federico Gatto et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Cabergoline Use for Pituitary Tumors and Valvular Disorders
Renata S. Auriemma et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2015)
Pharmacokinetics and Safety of Subcutaneous Pasireotide and Intramuscular Pasireotide Long-acting Release in Chinese Male Healthy Volunteers: A Phase I, Single-center, Open-label, Randomized Study
Xia Chen et al.
CLINICAL THERAPEUTICS (2014)
Prospective Study of Surgical Treatment of Acromegaly: Effects on Ghrelin, Weight, Adiposity, and Markers of CV Risk
Carlos Reyes-Vidal et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly
Andrea Giustina et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
Robert R. Henry et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study
Carla Giordano et al.
PITUITARY (2012)
Resistance to Somatostatin Analogs in Acromegaly
Annamaria Colao et al.
ENDOCRINE REVIEWS (2011)
Place of Cabergoline in Acromegaly: A Meta-Analysis
Laure Sandret et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Pasireotide and Octreotide Stimulate Distinct Patterns of sst2A Somatostatin Receptor Phosphorylation
Florian Poell et al.
MOLECULAR ENDOCRINOLOGY (2010)
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial
Andrea Giustina et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Acromegaly pathogenesis and treatment
Shlomo Melmed
JOURNAL OF CLINICAL INVESTIGATION (2009)
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
I. M. Holdaway et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Pasireotide (SOM230): Development, mechanism of action and potential applications
Herbert A. Schmid
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
分享论文
